Our goal is to discover and develop novel therapies for a range of I&I diseases. We aim to accomplish this goal by focusing on known biologic drivers of disease and utilizing advanced antibody engineering to develop product candidates with optimized properties that have the potential to overcome limitations of existing therapies. We believe our approach will enable us to develop a portfolio of therapies that are potentially differentiated compared to the currently available standards of care and address unmet medical needs for I&I diseases.
Our science
Reshaping the standard of care for inflammatory and immune diseases
Our science
Novel antibodies engineered against validated targets
At Apogee, we are advancing both monotherapies and rational combinations of therapeutic antibody product candidates. Our ongoing and planned clinical studies aim to study the safety and efficacy of our next generation product candidates to target I&I diseases. While traditional antibodies are broken down quickly within the body and have limited circulation time in the blood stream, Apogee’s antibodies are engineered to bind better to FcRn, which spares them from being broken down, allowing them to work for a longer amount of time.
Our antibody programs are designed to overcome limitations of existing therapies by leveraging well-established mechanisms and incorporating advanced antibody engineering to optimize half-life and other properties. Our ongoing study is testing APG777 dosed either every three or six months in maintenance, which, if our clinical trials are successful, would represent a significant improvement compared to currently available antibodies that are dosed every two to four weeks. We believe each of our programs has potential for broad application across multiple I&I indications.
Therapeutic targets
Apogee is progressing a pipeline of novel antibodies engineered against validated targets in some of the largest I&I markets.
IL-13
A clinically validated target in atopic dermatitis and eosinophilic esophagitis. It is a critical cytokine in inflammation and a primary driver of AD. In our head-to-head preclinical studies, APG777 demonstrated equivalent or better potency to lebrikizumab in the inhibition of IL-13 signaling.
IL-4Rα
A target with clinical validation across eight Type 2 allergic diseases.
OX40L
A clinically validated target in atopic dermatitis, located further upstream in the inflammatory pathway than IL-13 or IL-4Rα. Targeting OX40L could have broader impact on Type 1, 2, and 3 inflammation that is optimally positioned for combination with deep Type 2 inhibition provided by IL-13 targeting.
TSLP